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Abstract
Background: Up to 30 % of adults with severe asthma are hypersensitive to aspirin and no unambiguous theory
exists which provides a satisfactory explanation for the occurrence of aspirin-induced asthma (AIA) in some
asthmatic patients. Therefore, the aim of this study was to compare the AIA expression profile against aspirin
tolerant asthma (ATA) and healthy volunteers (HV) profile in peripheral blood mononuclear cells (PBMCs) after
in vitro aspirin challenge in Caucasian population.
Methods: PBMCs were separated from blood of three groups of subjects - 11 AIA, 7 ATA and 15 HV and then
stimulated by either 2 μM lysine aspirin or 20 μM lysine as a control. Subsequently, RNA was isolated, transcribed
into cDNA and subjected to microarray and qPCR studies. Simultaneously, protein was extracted from PBMCs and
used in further immunoblotting analysis.
Results: The validation of results at mRNA level has shown only three genes, whose expression was significantly
altered between comprising groups. mRNA expression of CNPY3 in PBMCs in AIA was significantly lower (-0.41 ± 2.67)
than in HV (1.04 ± 2.69), (p = 0.02); mRNA expression of FOSL1 in PBMCs in AIA was also significantly decreased
(-0.66 ± 2.97) as opposed to HV (0.31 ± 4.83), (p = 0.02). While mRNA expression of ERAS in PBMCs was increased
(1.15 ± 0.23) in AIA in comparison to HV (-1.32 ± 0.41), (p = 0.03). At protein level the changed expression of one protein
was confirmed. Protein expression of FOSL1 in PBMCs in AIA was both significantly lower (-0.86 ± 0.08) than in ATA
(0.39 ± 0.42), (p = 0.046) and in HV (0.9 ± 0.27), (p = 0.007).
Conclusions: This pilot study implies a positive association between CNPY3, ERAS, FOSL1 and aspirin-intolerant
asthma, suggesting that these findings would be useful for further investigations of NSAIDs mechanism.
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Background
Aspirin-exacerbated respiratory disease (AERD) is a dis-
tinct asthma phenotype mainly characterized by chronic
eosinophilic inflammation of the upper and lower airways
with symptoms that are exacerbated by aspirin and other
nonsteroidal anti-inflammatory drugs (NSAIDs) [1–4].
It is estimated that 0.6–2.5 % of total population [5, 6],
5–10 % of asthmatic adults [7–9], almost 30 % adults with
severe asthma [10] and just about 40 % of asthmatic adults
with refractory chronic hyperplastic sinusitis [11] are hy-
persensitive to aspirin (ASA). Emphatically, more than
15 % of asthmatic patients are quite unaware of suffering
from this intolerance [12] and only provocation tests may
reveal AIA. Higher incidence of AIA was also reported
in women in whom symptoms start earlier and disease
course is more rapid and severe [13].
Although the exact pathomechanism of AIA still remains
unknown, pathognomonic reactions to COX-1 active drugs
can be attenuated by inhibitors of 5-lipoxygenase (5-LOX),
type 1 receptor for cysteinyl leukotriens (cysLTR1) [14]
and by drugs that block mast cells (MA) activation
[15, 16]. Moreover, inhaled prostaglandin E2 (PGE2)
inhibits aspirin - induced bronchoconstriction and
cysLT production in subjects with AERD [17]. PGE2
is formed from COX-dependent conversion of arachi-
donic acid to PGH2, which is metabolized to PGE2 by
three PGE2 synthases (PGESs) [18]: cytosolic PGES
and microsomal PGES (mPGES-1 and mPGES-2) [19, 20].
Absence of mPGES-1 impairs the up-regulation of PGE2
production in mice [21]. Additionally PGES-/- mice de-
velop marked eosinophil - dominated bronchovascular
cellular infiltrates with lesser numbers of neutrophiles
[22, 23] and lysine aspirin (Lys-ASA) challenge caused
additively releases of two markers of MC activation –
histamine, mMCP-1 and cysLTs [21]. The marked de-
pletion of residual PGE2 by Lys-ASA in the PGES
-/-
mice suggests that mPGES-1 sustains PGE2 generation in
the face of COX-1 inhibition [21]. It has been also demon-
strated that platelet- adherent eosinophils and neutrophils
are more frequent in the peripheral blood and sinonasal
tissues from patients with AERD than in samples from as-
pirin tolerant controls [24]. Adherence to platelets primes
granulocyte integrin function [25], chemotaxis [26] and
increase susceptibility to inflammation [21]. It is probably
that TP receptors are essential for platelet-adherent gran-
ulocytes to generate cysLTs by facilitating cross – talk be-
tween platelets and granulocytes [21]. Though the residual
local PGE2 derives principally from COX-1, which may
explain why only COX-1 – active drugs provoke clinical
reactions [27].
It is also known that the production of 15–hydro-
xyeicosatetranoic acid (15–HETE) in AIA patients is
3.6 fold higher than in ATA patients [28]. The sub-
stantial source of 15–HETE in this reaction seems to
be 15–lipooxygenase (15–LOX) that is controlled by
COX-1 [29]. Thus, inhibition of COX-1 and disregulation
of PGE2 production by aspirin results in activation of 15-
LOX and 15-HETE production [28]. Overproduction of
15-HETE in aspirin sensitive asthmatics inter alia contrib-
utes to the induction of mucous glycoprotein secretion by
human airway [30] and contraction of bronchial smooth
muscles [31]. According to these results in – vitro test
(ASPItest) is known that measures ASA – induced 15 –
HETE in peripheral blood. ASPItest does not require spe-
cial expertise, equipment and seems to be highly sensitive
and specific to confirm the history of aspirin sensitivity in
asthmatic patients [29].
So far, in the literature there is also a lot of data con-
cerning genetic mechanisms suggesting the involvement
of various candidate genes in the pathogenesis of AIA.
Unfortunately, the majority of these results is not con-
sistent between various populations indicating environ-
mental factors which may predestine to development of
AIA. Moreover, the likelihood that AIA is acquired in
adulthood implies potential epigenetic modifications of
the relevant mediator systems. Hence, it has been dem-
onstrated that PGE2 synthase gene in nasal polyps from
subjects with AERD is hypermethylated in comparison
to nasal polyps from aspirin – tolerant controls [32].
The aim of this study was to explore the possible dif-
ference between aspirin-induced asthma (AIA), aspirin
tolerant asthma (ATA) and HV (healthy volunteers) gen-
etic profiles in PBMCs in Caucasian population by means
of whole genome scan after in vitro aspirin challenge.
Methods
Study subjects
Subjects of Caucasian origin were recruited from Depart-
ment of Internal Medicine, Asthma and Allergy; Medical
University of Lodz; Poland. The diagnosis of bronchial
asthma was based on an patient’s history, physical examin-
ation and pulmonary function tests according to Global
Initiative for Asthma (GINA) 2014 guidelines. Asthmatic
patients were included in the study if they met the follow-
ing criteria: clinical diagnosis of asthma confirmed by
bronchial hyperactivity assessed by a positive broncho-
dilator or methacholine test, the incidence of asthmatic
attacks and no other respiratory disorders. Patients were
asked to refrain from short acting bronchodilators for at
least six hours before challenge.
Aspirin–sensitive asthmatic subjects were included in
the study if they had a positive oral provocation test with
aspirin during the last 6 months, made without the con-
text of the study. Patients with aspirin-tolerant asthma
and healthy subjects were involved in the project if they
had had a negative history of aspirin or other NSAIDs
hypersensitivity and had been exposed to these medica-
ments during at least the last six months without any
Wieczfinska et al. Respiratory Research  (2015) 16:147 Page 2 of 15
adverse events before the study. The clinical profiles of
asthma patients and healthy control subjects are sum-
marized in Table 1. The study protocol was approved by
the Ethics Committee of the Medical University of Lodz
(permission no. RNN/107/08/KE, RNN/103/11/KE) and
written consent was obtained from every subject prior to
the study.
PBMCs isolation and incubation with lysine aspirin/lysine
Peripheral venous blood was collected before aspirin
challenge. PBMCs were separated using Histopaque®
1077 solution (Sigma Aldrich, Saint Louis, MO) according
to the manufacturer’s protocol, washed three times in
PBS. Afterwards, the PBMCs were incubated either wuth
lysine aspirin (2 μM) or lysine (20 μM) for 30 min at 37 °C.
Incubation conditions for the cells were selected on the
basis of previous, unpublished pilot studies. PBMC counts
were not statistically different between groups before and
after incubation with lysine aspirin or lysine.
cDNA synthesis and microarray hybridization
RNA was isolated (RNAeasy Mini Kit, Qiashredder
(Qiagen, Hilden, Germany) and trascribed into cDNA
(ImProm II Reverse Transcription Kit (Promega, Madison,
Wisconsin)), which was subjected to microarray analysis.
Microarray procedures
Microarray flip dye experiments were performed with
Human OneArray® Whole Genome Microarrays v 5.1
(Phalanx Biotech, San Diego, CA) containing 30,255 oligo-
nucleotide probes (29,187 human genome probes and
1,088 experimental control probes) was used for gene ex-
pression analysis. Each sample was hybridized against
Universal Human Reference RNA (Stratagene, La Jolla,
CA, USA) provided a common denominator for accurate
and reproducible comparisons of gene expression data.
Single-stranded cDNA samples were labelled with Cy3
and Cy5 using ULS™ Labelling Kit (Kreatech Diagnostics,
Netherlands).
Synthesis of target cDNA probes and hybridization were
performed according to protocol. The preparation of a
slide for hybridization included pre-wash in ethanol and
pre-hybridization according to manufacturer’s protocol.
Hybridization was performed in a humidity chamber
filled with 2× SSPE buffer at 42 °C for 16–18 h. Post-
hybridization washes were performed with the following
buffers: 1× SSPE/0.03 % SDS (2 min, 42 °C), 1× SSPE
(2 min, RT) and 0.1× SSPE (rinsed several times, RT).
qPCR for candidate genes
cDNA was subjected to qPCR using the kits of primers
and probes designed for the selected genes and GAPDH
as a qPCR reference (Life Technologies, Carlsbad, CA).
Assay ID and contex sequences used in this study are
shown in Table 2. Each sample was measured in dupli-
cate using TaqMan analyzer 7900 (Life Technologies,
Carlsbad, CA). Using the 2-ΔΔCt method, data are pre-
sented as a fold change in gene expression normalized
to endogenous reference gene GAPDH and relative to a
control (lysine-treated PBMCs). The fold change of
mRNA expression in each patient was calculated by
comparing RQ (2-ΔΔCt).
Protein isolation and immunoblotting analysis
Total protein was isolated utilizing RIPA lysis buffer
(Sigma, Saint Louis, MO) with addition of Protease In-
hibitor Cocktail (Sigma, Saint Louis, MO) according to
manufacturer’s protocol and analyzed by immunoblot-
ting method to detect selected proteins (Table 3) using
10 μg total protein per sample. Detailed immunoblotting
protocol is provided in Additional file 1.
Table 1 Characteristics of recruited aspirin - sensitive asthmatics, aspirin - tolerant asthmatics and healthy volunteers
Aspirin - sensitive asthmatics Aspirin - tolerant asthmatics Healthy volunteers
Number of subjects (n) 11 7 15
Gender (n, female/male) 6/5 3/4 11/4
Age (years, median (range)) 39 (21–71) 44 (30–67) 30 (21–58)
FEV1 (% predicted) 81.45 ± 19.36 88.43 ± 7.89
PEF (% predicted) 89.14 ± 20.24 84.64 ± 20.47
Inhaled GCS (μg/day, mean (range))a 1200 (0–2400) 1120 (400–2400)
Systemic GCS (mg/day, mean (range))b 0 0 (0–12)
Current smokers (%) 27.3 14.3
Subjects with sinusitis (%) 63.6 85.7
Subjects with rhinitis (%) 72.7 100
Subjects with atopy (%) 45.5 85.7
ainhaled GCS were calculated as budesonide equivalents, bsystemic GCS were calculated as prednisone equivalents
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Statistical analysis
Microarray studies
For microarray studies, detection of p values and nor-
malization were performed for the extracted values. Stat-
istical significance of the microarray data was calculated
by the Student’s t test – standard two-sample t-statistics
with pooled variance. Additional statistical analysis was
performed using the false discovery rate (FDR) to correct
for multiple comparisons in multiple hypothesis testing.
FDR of a test was defined as the expected proportion of
false positives among the declared significant results
[33, 34] as it is a more convenient scale to work on
instead of the p-value scale [35]; it is not too conser-
vative for microarray studies and does not lead to low
sensitivity [35].
For the diagnostic values of gene expression in the
discrimination of AIA from ATA and healthy sub-
jects, we selected candidate genes that satisfied the
criteria of p < 0.05 and exhibiting change in expres-
sion greater than twofold difference between the two
chosen groups. For microarray analysis, background-
corrected values for each probe on oligonucleotide
array were extracted using MeV software (TM4,
Boston, MA).
qPCR and immunoblotting analysis
For qPCR and immunoblotting results, the distribution
of the log2data and the equality of variances were
checked by Shapiro-Wilk and Levene’s tests, respectively.
The results were presented as mean ± SEM when data in
groups were normally distributed; differences between
groups were examined for statistical significance by
ANOVA with the appropriate post-hoc test. If Kruskal -
Wallis test (with multiple comparison) - non-parametric
equivalent of ANOVA was used, the results were pre-
sented as median ± range.
P value < 0.05 was considered as statistically significant.
The data from the study was analyzed utilizing STATIS-
TICA software package (Statsoft, Tulsa, OK).
Table 2 qPCR probes used for expression analysis of specified
genes
Gene names Context sequence*(5’ to 3’) Catalog number
ALOX5 GGAGGTCCAGCAAGGGAAACA Hs01095330_m1
ALOX15 TATCTTCAAGCTTATAATTCC Hs00609608_m1
BMP2 CACCATGAAGAATCTTTGGAA Hs00154192_m1
CNPY3 CCAAGGGCATGTCAGAGACCT Hs00198139_m1
CSF1 CATGACAAGGCCTGCGTCCGA Hs00174164_m1
CXCL11 ACAGTTGTTCAAGGCTTCCCC Hs00171138_m1
DOCK9 TTAAGTTGCTGCGAAACCAGA Hs00324508_m1
DPP9 CTACCTGGGAATGCCATATGG Hs00373589_m1
ERAS CGAGTGTTGTGTGGGTGGGAG Hs00742161_s1
FOSL1 CCCAGCAGAAGTTCCACCTGG Hs04187685_m1
GAB3 ACCTGGAAAGCTGATGTAGAA Hs00369794_m1
MARVELD1 GGGCCTGTAAGGTTTCCATGT Hs00230362_m1
PARVG AGCCTCCAAAGGACGTCTTTG Hs00223323_m1
RXRG CAGATCCTCAGGAAAGCACTA Hs00199455_m1
TLR7 ACTAAAAATGGTGTTTCCAAT Hs00152971_m1
TRIP6 TGAGGACTTTCACAGGAAGTT Hs00377979_m1
*Assays ordered from Life Technologies are provided with context sequence
surrounding the assay location. Probes contain typically 13–18 bases and the
minor groove binder (5–6 bases on 3’ end stabilizing the probe)
Table 3 Primary antibodies used for immunoblotting
Protein names Primary antibody Dilution Producer Catalog number
ALOX5 Rabbit polyclonal 1:1000 Cell Signalling 3748
ALOX15 Rabbit polyclonal 1 mg/ml Aviva Systems Biology ARP56030_P050
BMP2 Rabbit polyclonal 1:1000 Abnova H00000650-D01P
CNPY3 Rabbit polyclonal 0.2 μg/ml Aviva Systems Biology ARP34422_P050
CSF1 Rabbit polyclonal 1/100 Abcam ab93335
CXCL11 Rabbit polyclonal 0.2 μg/ml Abcam ab9955
DOCK9 Rabbit polyclonal 1/5000 Abcam ab70272
DPP9 Rabbit polyclonal 1/2500 Abcam ab42080
ERAS Rabbit polyclonal 0.2 μg/ml Aviva Systems Biology ARP55794_P050
FOSL1 Rabbit monoclonal 1:1000 Cell Signalling 5281
GAB3 Rabbit polyclonal 1/250 Abcam ab121311
MARVELD1 Rabbit polyclonal 1 μg/ml Abcam ab91640
PARVG Rabbit polyclonal 1:1000 Abnova H00064098-D01P
RXRG Rabbit polyclonal 1:1000 Cell Signalling 5629
TLR7 Rabbit Polyclonal 1:5000 GeneTex GTX125910
TRIP6 Rabbit polyclonal 0.2 μg/ml Aviva Systems Biology ARP51617_P050
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Power analysis
Sample size was calculated based on the number of
aspirin sensitive patients counted per total population of
Poland (6). Based on Daniel formula for calculating
sample size (29), this gave a calculated AIA sample size
approximately 9 patients. However, a higher number was
targeted in qPCR in order to account for possible exclu-
sions, dropouts and the need to carry out subgroup
analysis.
Results
Comparison of gene expression profiles between AIA
versus ATA and AIA versus healthy volunteers
The gene expression microarray consisting of 30.255 fea-
tured oligonucleotide probes to cDNA samples obtained
from AIA (n = 5), ATA (n = 3) and healthy volunteers
(n = 4) was applied. To evaluate the overall difference
in gene expression levels in PBMCs among AIA, ATA
and healthy volunteers, we calculated the gene expression
level using a volcano plot (Figs. 1 and 2). Volcano plot
against fold change values for each gene revealed that the
expression levels were slightly different between AIA ver-
sus ATA and AIA versus healthy subjects. We identified
genes that showed 325 significantly different expression
between AIA vs. ATA (253 genes that showed a significant
increase in gene expression and 72 genes that showed a
significant decrease) and 376 genes with significantly
changed expression between AIA versus healthy volun-
teers – 196 genes turned out to be significantly increased
and 180 genes with statistically significant decreased ex-
pression (Figs. 3 and 4).
For the next step of analysis, we selected genes DPP9,
RXRG and FOSL1 with a p value of <0.05 and mean dif-
ference in fold change value >2 between the two
chosen groups (Fig. 5). Differences in gene expression
obtained in whole genome scan using cDNA microar-
rays was shown in Table 4. The role of selected genes
in inflammation or asthma had been confirmed in litera-
ture before. The upregulated and downregulated genes
were perfectly classified by the hierarchical clustering
method.
Verification of gene expression with quantitative
measurement of mRNA using qPCR
We validated three previously selected genes: DPP9,
RXRG and FOSL1 using qPCR to measure their mRNA
levels in PBMCs obtained from AIA (n = 11), ATA (n = 7)
and healthy volunteers (n = 15). Therefore qPCR was ana-
lyzed for original microarray patients’ group and additional
patients were added to have a confirmatory cohort.
Quantification of mRNA levels was performed by
measuring the amount of DPP9, RXRG and FOSL1 qPCR
product after correcting for amount of GAPDH. Addition-
ally, qPCR analysis included validation of such genes as
ALOX5, ALOX15, BMP2, CNPY3, CNPY3, CSF1, CXCL11,
DOCK9, ERAS, GAB3, MARVELD1, PARVG, TLR7 and
TRIP6 – markers of inflammation, formerly described in
literature.
Fig. 1 Volcano plot and result of hierarchical clustering for p < 0.05 obtained for aspirin-induced asthma and aspirin-tolerant asthma patients
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mRNA expression of selected genes
mRNA expression of CNPY3 in PBMCs in AIA was
significantly lower (-0.41 ± 2.67) than in healthy group
(1.04 ± 2.69), (p = 0.02). However, expression of the mRNA
of CNPY3 in PBMCs was not significantly different be-
tween AIA and ATA (0.52 ± 2.15), (p = 0.08) and ATA vs.
healthy group (p = 1.00); (Fig. 6a).
mRNA expression of ERAS in PBMCs in AIA was
significantly higher (1.15 ± 0.23) than in healthy group
(-1.32 ± 0.41), (p = 0.03). While, expression of the mRNA
of ERAS in PBMCs was not significantly different between
AIA and ATA (-0.52 ± 0.72), (p = 0.18) and ATA vs.
healthy group (p = 0.65); (Fig. 6b).
mRNA expression of FOSL1 in PBMCs in AIA was
significantly lower (-0.66 ± 2.97) than in healthy group
(0.31 ± 4.83), (p = 0.02). However, FOSL1 mRNA expres-
sion in PBMCs was not significantly changed between
AIA and ATA (-0.09 ± 3.03), (p = 0.54) and ATA vs.
healthy group (p = 0.78); (Fig. 6c).
mRNA expression of the following genes in PBMCs
was not significantly changed after aspirin-lysine and
lysine incubation:
ALOX5 - AIA (0.01 ± 0.28) vs. ATA (0.23 ± 0.35),
(p = 0.894) and healthy volunteers (-0.04 ± 0.27); (p =
0,99) (Fig. 7a), ALOX15 - AIA (-0.05 ± 0.86) vs. ATA
(-1.18 ± 0.75), (p = 0.5) and healthy volunteers (-1.07 ±
0.36), (p = 0.52); (Fig. 7b).
DOCK9 - AIA (0.59 ± 0.42) vs. ATA (-0.21 ± 0.26),
(p = 0.39) and healthy volunteers (-0.12 ± 0.31), (p = 0.42);
(Fig. 7c), MARVELD1 - AIA (-0.37 ± 0.18) vs. ATA
(-0.27 ± 0.4), (p = 0.97) and healthy volunteers (0.35 ±
0.23), (p = 0.15); (Fig. 7d).
PARVG - AIA (-0.35 ± 1.93) vs. ATA (0.07 ± 1.2), (p =
0.14) and healthy volunteers (-0.12 ± 0.92), (p = 0.77);
(Fig. 7e), and TLR7 - AIA (-0.09 ± 0.33) vs. ATA (-0.33 ±
0.15), (p = 0.8) and healthy volunteers (0.04 ± 0.11),
(p = 0.9); (Fig. 7f ).
Moreover, no statistically significant changes were
observed in the following genes mRNA expression:
BMP2 - AIA (-0.22 ± 0.25) vs. ATA (0.26 ± 0.23), (p =
0.72) and healthy volunteers (-0.20 ± 0.31), (p = 1); (Fig. 7g),
CSF1 - AIA (-0.8 ± 0.28) vs. ATA (-0.03 ± 0.18), (p = 0.23)
and healthy volunteers (-0.27 ± 0.21), (p = 0.31); (Fig. 7h).
CXCL11 - AIA (-0.33 ± 0.33) vs. ATA (0.4 ± 0.15), (p=
0.41) and healthy volunteers (-0.57 ± 0.35), (p= 0.87); (Fig. 7i),
DPP9 - AIA (0.28 ± 4.12) vs. ATA (0.24 ± 2.34), (p = 1) and
healthy volunteers (0.16 ± 3.8), (p = 1.0); (Fig. 7j).
mRNA expression of GAB3 in PBMCs was also not
significantly changed between AIA (-0.06 ± 0.13) versus
ATA (0.14 ± 0.25), (p = 0.75) and healthy patients (-0.13 ±
0.12), (p = 0.95); (Fig. 7k), similarly, TRIP6 in PBMCs -
AIA (-0.25 ± 1.46) vs. ATA (0.26 ± 2.73), (p = 1) and
healthy patients (-0.03 ± 3.43), (p = 1); (Fig. 7l).
Verification of gene expression with quantitative
measurement of protein using immunoblotting analysis
Comparison of protein expression encoded by selected
genes between AIA (n = 6), ATA (n = 6) and healthy
Fig. 2 Volcano plot and result of hierarchical clustering for p < 0.05 obtained for healthy subjects and aspirin-induced asthma patients
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volunteers (n = 7) groups was done by means of immu-
noblotting. Quantification of ALOX5, ALOX15, BMP2,
CNPY3, CSF1, CXCL11, DOCK9, DPP9, ERAS, FOSL1,
GAB3, MARVELD1, PARVG, TLR7, TRIP6 protein
levels was performed by measuring the protein product
amount after stimulation of PBMCs with lysine aspirin
and correcting for obtained protein amount after stimu-
lation of PBMCs with lysine. Further, quantification of
protein levels on the basis of obtained bands after stimu-
lation with lysine aspirin and lysine was analyzed on the
same gel for each patients. Sharp bands for BMP2,
CNPY3, CSF1, CXCL11, DPP9 ERAS, FOSL1, GAB3
and TRIP6 appeared in the expected positions. In the case
of other selected genes, no or faint bands (weak signal)
were obtained.
Selected proteins expression
CNPY3 protein expression in PBMCs was not signi-
ficantly changed between AIA (0.26 ± 0.55) vs. ATA
(-0.33 ± 0.16), (p = 0.58) and healthy patients (-0.56 ±
0.47), (p = 0.41); (Fig. 8a), same as ERAS protein expres-
sion - AIA (0.68 ± 0.21) vs. ATA (-0.67 ± 0.75), (p = 0.37)
and healthy patients (-0.56 ± 0.67), (p = 0.38); (Fig. 8b).
Protein expression of FOSL1 in PBMCs in AIA was
significantly lower (-0.86 ± 0.08) in comparison to ATA
(0.39 ± 0.42), (p = 0.046) and to healthy subjects (0.9 ±
0.27), (p = 0.007). However, FOSL1 protein expression in
PBMCs was not significantly changed between ATA vs.
healthy group (p = 0.487); (Fig. 8c). Immunobloting results
are shown in the Fig. 9.
Fig. 3 Venn diagram of overlap between gene numbers predicted
from microarray, qPCR and immunoblotting methods for AIA versus
ATA (a) and AIA versus HV (b)
Fig. 4 Number of genes with differential expression between groups with up-regulated genes being predominant on AIA versus ATA and AIA
versus healthy volunteers. PBMCs were separated from blood of three groups of subjects - 11 AIA, 7 ATA and 15 HV and stimulated by either
lysine aspirin or lysine as a control. The gene expression presented was analyzed utilizing microarray technique
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Changes in expression of the other proteins were not sta-
tistically significant: BMP2 protein expression in PBMCs
was not significantly changed between AIA (0.28 ± 0.5) vs.
ATA (-0.36 ± 0.46), (p = 0.58) and healthy patients (-0.76 ±
0.26), (p = 0.2); (Fig. 10a), the same as CSF1 protein - AIA
(-0.85 ± 0.2) vs. ATA (0.39 ± 0.6), (p = 0.34) and healthy pa-
tients (-0.59 ± 1.0), (p = 0.9); (Fig. 10b), and CXCL11 - AIA
(-0.25 ± 0.67) vs. ATA (-0.46 ± 0.28), (p = 0.94) and healthy
patients (0.77 ± 0.28), (p = 0.28); (Fig. 10c).
DPP9 protein expression in PBMCs was not significantly
changed between AIA (-0.37 ± 0.4) vs. ATA (-0.2 ± 0.12),
(p = 0.91) and healthy patients (-0.07 ± 0.16), (p = 0.76);
(Fig. 10d), the same as GAB3 protein expression - AIA
(-0.12 ± 0.16) vs. ATA (0.06 ± 0.18), (p = 0.74) and healthy
patients (-0.07 ± 0.14), (p = 0.98); (Fig. 10e), and TRIP6
protein - AIA (0.66 ± 0.5) vs. ATA (-0.14 ± 0.28), (p = 0.54)
and healthy patients (0.08 ± 0.55), (p = 0.72); (Fig. 10f).
Discussion
Considering the genetic background of AIA, more than
100 genetic association studies have attempted to dis-
cover the numerous genetic variants related to develop-
ment of AIA. However, the majority of these results
have not been replicated in other, independent studies.
Moreover, to the best of our knowledge, two published
papers based on both microarray study and qPCR con-
firmation reveal the involvement of individual genes in
the pathogenesis of AIA. However neither of which were
also confirmed in other studies and population.
The first, whole-genome study [36] demonstrated that
galactin-10 mRNA is overexpressed in peripheral blood
cells of AIA compared to ATA patients and controls.
Galactin-10 had been previously implicated in mucosal
inflammatory processes including cell adhesion [37],
chemoattraction [38] and cell activation [39]. Whereas,
the second study [40] showed two genes – CNKSR3 and
SPTBN2 which expression in PBMCs differentiates be-
tween AIA and ATA, but neither CNKSR3 nor SPTBN2
has described relationship with asthma and aspirin.
As in previous whole genome studies, the main aim of
our investigation was to compare the AIA genetic profile
against ATA and HV in PBMCs by microarray studies
and then confirm it on protein level. The verification on
two molecular levels was necessary because mRNA
levels cannot be utilized as surrogates for corresponding
protein levels. Although RNAs are primordial molecules,
proteins are the molecules of life and it is estimated that
only less than 40 % of cellular protein levels can be pre-
dicted from mRNA measurements [41]. The most known,
presumable reasons for the poor correlations reported in
literature between the level of mRNA and protein are: (a)
many complicated and varied post-transcriptional mecha-
nisms involved in turning mRNA into protein – the cell
can control the levels of gene at transcriptional level and/
or translational level [42]; (b) difference in half-lives of
proteins as the result of varied protein synthesis and deg-
radation depending on a number of different conditions;
(c) significant amount of error in mRNA/protein studies
[43, 44]. Intriguingly, genes with certain combinations of
mRNA and protein half-lives share common functions, in-
dicating that they evolved under similar constraints such
as abrupt respond to stimulus [41, 45–47]. Most mRNAs
and especially proteins are stable unless genes need to re-
spond quickly to a stimulus [41]. However, measurements
performed at mRNA and protein levels are complemen-
tary and both are necessary for a complete understanding
how the cell works [48].
On the basis of obtained results, we identified three
genes whose expression profiles significantly differed be-
tween AIA vs. ATA and/or AIA vs. healthy subjects in
PBMCs of Caucasian population. We demonstrated sig-
nificant decrease in expression of FOSL1 (encoding FRA1)
at either mRNA or protein level in patients diagnosed
Fig. 5 Heat map of selected genes of AIA and ATA subjects (p < 0.05) (a), as well as healthy controls and AIA subjects (p < 0.05) (b)
Table 4 Differences in gene expression obtained in whole
genome scan using cDNA microarrays
No Gene symbol AIA mean ATA mean p value FDR
1 DPP9 1,29 - 1,20 1,23 · 10−5 0,009
2 RXRG 1,28 - 1,80 2,61 · 10−4 0,089
No Gene symbol AIA mean HV mean p value FDR
3 FOSL1 −0,39 2,42 0,044 1,189
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with AIA in comparison to ATA and controls. FOSL1 is a
part of AP-1 – transcription factor that regulates target
gene expression in response to various pro-oxidants, in-
flammatory cytokines including TGFβ1 [49, 50], environ-
mental toxicants, carcinogens and pathogens. These gene
products mediate oxidative stress and inflammatory re-
sponses, as well as cell growth and tumorgenesis [51].
Additionally, TGF-β1 promoter (509C/T) polymorphism
has been reported to contribute to the development of
AIA with rhinosinusitis by increasing TGF-β production
in the nasal mucosa and/or polyp tissues of patients with
AIA [52]. Tang et al. showed that aspirin-treated bone
marrow cells have significantly improved immunomodu-
latory function, as indicated by upregulation of regulatory
T cells and downregulation of Th17 cells via, inter alia
TGF-β1 pathway [53].
Moreover, FOSL1 regulates the expression of genes
controlling tissue/cell remodeling, mainly at transcrip-
tional level [54–56]. Rajasekaran et al. [57] have recently
shown that FRA1-/- mice are more susceptible than wild-
type mice to bleomycin - induced fibrosis, suggesting that
this transcriptional factor is involved in pulmonary protec-
tion. To emphasize this hypothesis, downregulation of
FOSL1 was also observed in malignant human bronchial
epithelial cells [55] and non-small-cell lung cancer [58]
compared to normal bronchial epithelium.
Comparison of genetic profile between AIA and healthy
controls has also demonstrated significantly increased
expression of ERAS in AIA. Actually the role of this gene
is restricted to the tumor - like growth properties of em-
bryonic stem cells [59] and chemotherapy resistance [60].
However, ERAS belongs to GTPase Ras protein family en-
gaged in airway smooth muscle growth and bronchocon-
striction of airways in response to stimuli [61]. Among all
proteins that belong to Ras superfamily, Rho kinase has
emerged as a potential target for the treatment of airway
hyperresponsiveness in asthma [62]. Additionally, arachi-
donic acid (AA) can activate Rho kinase by binding to the
C-terminal part of the coiled-coil domain of Rho kinase,
which acts as an auto-inhibitor domain [63–65]. Rho
kinase may also be involved in eotaxin and cytokine (IL-5,
IL-13) production [66] and in secretion of matrix me-
talloproteinase – 9 (MMP-9), tightly associated with
fibrosis in asthma and chronic obstructive pulmonary
disease (COPD) [67, 68]. It is worth mentioning, as the
extent of Ras activation in T cells appears to drive Th2
Fig. 6 mRNA expression levels of CNPY3 a, FOSL1 b and ERAS c genes in PBMCs measured by qPCR between AIA (n = 11), ATA (n = 7) and
healthy volunteers (n = 15). PBMCs were stimulated by lysine-aspirin or lysine as a control. The gene expression presented was analyzed utilizing
Real-Time PCR. * statistically significant (p < 0.05)
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dependent eosinophilic airway inflammation and allergen-
induced airway hyperresponsiveness [69]. Much evidence
indicates also that Ras GTPases appear to regulate reactive
oxygen species (ROS) production and oxidants function
as effector molecules for the small GTPases [70–73]. Rac1
has been demonstrated to act upstream of AA – metabol-
izing enzymes, such as PLA2 [74, 75], 5-LOX [76–78] and
COX-2 [79] and thus some reports show that AA metab-
olism modulates NADPH oxidase and mitochondrial ROS
production [80].
The misregulation of the redox signaling of Ras with
its downstream cascades also has been linked to various
disorders linked with immune system [81]. According to
Wells et al. [82], Ras-dependent Raf-MEK1/2-ERK1/2
pathway takes part in postnatal modulation of a host’s
defenses and the inflammation of T lymphocytes. In a
mouse allergic asthma model, the activation of Ras in T
cells controls the development of Th2-dependent
eosinophilic airway inflammation and airway hyperre-
sponsiveness. Specific inhibitors focusing on Ras-
mediated signaling pathways would be thus helpful in
treatment approach of asthma [69].
Although ERAS was one of the genes indicating asso-
ciation with aspirin-induced asthma in our study, there
are only single data supporting its role. Nevertheless, re-
cently, Park et al. [83] have shown a strong association
between the SNPs (14444 T > G and 41170 C > G) within
RAB1A (Ras protein subfamily member) and the aspirin-
induced decrease in FEV1. The authors indicate also, that
genetic alteration of the member RAS oncogene family
may be related to the development of asthma and ASA
hypersensitivity through the modulation of intracellular
protein trafficking.
Multiple points of overproduction or underproduction
of critical inflammatory mediators may be determined by
metabolism through the Ras family GTPase pathway. The
Fig. 7 Box plot for mRNA expression levels of ALOX5 a, ALOX15 b, DOCK9 c, MARVELD1 d, PARVG e, TLR7 f BMP2 g, CSF1 h, CXCL11 i, DPP9 j, GAB3
k, and TRIP6 l genes in PBMCs measured by qPCR between AIA (n = 11), ATA (n = 7) and healthy volunteers (n = 15). PBMCs were stimulated by
lysine-aspirin or lysine as a control. The gene expression presented was analyzed utilizing Real-Time PCR
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release of specific granules from platelets, eosinophils, and
neutrophils depends on the phosphorylation of the Ras
family proteins [81], but detailed mechanism associated
with aspirin-induced asthma needs to be evaluated.
Significantly reduced expression of CNPY3 at mRNA
level in AIA in comparison to healthy controls may indi-
cate a profound defect in stimulus responsiveness. CNPY3
is an endoplasmic reticulum - resident chaperone that is
required for maturation/ glucosylation and surface traf-
ficking of TLR4 [84]. Activated TLR4 can directly or indir-
ectly affect the function of regulatory T cells, thus
influencing the Th1/Th2 imbalance and reducing inflam-
matory responses [85–87].
It is well known, that TLR4 is important component
in the innate immune response to lipopolysaccharide
(LPS) of gram-negative bacteria and the fusion protein
of respiratory syncytial virus (RSV) [88]. Therefore,
CNPY3 knockdown led to significant defect in RSV and
LPS responsiveness and limit innate immune responses
[84, 89]. By contrast, patients with AIA much more fre-
quently suffer from virus infection [90] and RSV is
probably one of the trigger predisposing to aspirin
hypersensitivity [91].
TLR4 is activated following binding of LPS, and a
series of downstream phosphorylation and dephospho-
rylation events eventually leads to the activation of
transcription factors that regulate inflammatory factors
including interferon, tumor necrosis factor; it also induces
antigen-presenting cell maturation and promotes a Th0 to
Th1 shift [85, 92]. According to Steinke et al. [93], high
levels of mentioned IFN-γ distinguish AERD (aspirin-ex-
acerbated respiratory disease) from aspirin tolerant asthma
and underlie the robust constitutive and aspirin-induced
secretion of CysLTs that characterize this disorder, as
AERD is associated with eosinophils maturing locally in a
high interferon (IFN)-γ.
To better understand the contribution of TLR4 to
aspirin-induced asthma pathogenesis, additional studies
are needed to determine the contribution of CNPY3 in
aspitin-induced asthma.
Our data also demonstrate that similar microarray
scores for different genes do not necessarily mean that
similar qPCR scores was obtained. This finding presum-
ably reflects the different hybridization kinetics of the
probe sets for each gene. Furthermore, varied priming
methods and increased distance between the location of
Fig. 8 Protein expression levels of CNPY3 a, FOSL1 b and ERAS c genes in PBMCs measured by qPCR between AIA (n = 11), ATA (n = 7) and
healthy volunteers (n = 15). PBMCs were stimulated by lysine-aspirin or lysine as a control. Protein data are presented as the fold change of optical
density (OD) compared with the lysine – treated cells. *statistically significant (p < 0.05)
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Fig. 9 Protein expression measured by immunoblotting between AIA, ATA and healthy volunteers. The blots shown are a representative of at
least six separate experiments that gave similar results
Fig. 10 Box plot for protein expression levels of BMP2 a, CSF1 b, CXCL11 c, DPP9 d, GAB3 e and TRIP6 f genes in PBMCs measured by qPCR between AIA
(n= 11), ATA (n= 7) and healthy volunteers (n= 15). Data are presented as the fold change of optical density (OD) compared with the lysine – treated cells
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the PCR primers and microarray probes on a given gene
can also affect the results of qPCR and microarray expe-
riments. In addition, data normalization fundamentally
differs between microarray analysis and qPCR, the former
requiring global normalization, while the latter generally
utilizes the expression of one reference gene against
which all other gene expression is calibrated. There-
fore, on the basis of the qPCR data that we obtained, it is
generally not feasible to predict the true expression level
of one gene based on the microarray expression score of
another.
Conclusions
To sum up, altered expression of three genes: ERAS,
CNPY3 and FOSL1 have been reported at mRNA level
in PBMCs of Caucasian aspirin-sensitive asthmatics as
opposed to healthy volunteers. In the case of FOSL1, this
difference was also confirmed at protein level, both - be-
tween AIA vs. ATA and AIA vs. HV. To our knowledge,
this is the first whole-genome study for AIA that points
out the positive association between ERAS, CNPY3,
FOSL1 and NSAIDs metabolism. However, some previous
studies have indicated participation of these genes in path-
ways significant for pathomechanism of AIA resulting in
tissue/cell remodeling and airway hyperresponsiveness.
Although our study included small number of patients, it
allowed to perform statistical analysis. Undoubtedly,
further studies in a larger number of cases and of other
ethnicity are necessary to establish an exact functional link
among the detected alternations in expression of CNPY3,
ERAS and FOSL1 with pathology of AIA.
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